<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To assess the efficacy and safety of pramlintide in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> suboptimally controlled with basal insulin </plain></SENT>
<SENT sid="1" pm="."><plain>RESEARCH DESIGN AND METHODS: In a 16-week, double-blind, placebo-controlled study, 212 patients using insulin glargine with or without oral antidiabetes agents (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OAs</z:e>) were randomized to addition of pramlintide (60 or 120 microg b.i.d./t.i.d.) or placebo </plain></SENT>
<SENT sid="2" pm="."><plain>Insulin glargine was adjusted to target a fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> concentration of 70-100 mg/dl </plain></SENT>
<SENT sid="3" pm="."><plain>One coprimary end point was the change in A1C at week 16 </plain></SENT>
<SENT sid="4" pm="."><plain>The other coprimary end point was a composite measure of overall <z:mp ids='MP_0002055'>diabetes</z:mp> control comprising A1C &lt; or = 7.0% or reduction &gt; or = 0.5%, mean daily postprandial <z:chebi fb="105" ids="17234">glucose</z:chebi> (<z:chebi fb="73" ids="53262">PPG</z:chebi>) increments &lt; or = 40 mg/dl, no increase in body weight, and no severe <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Patients meeting <z:hpo ids='HP_0000001'>all</z:hpo> four conditions at week 16 achieved this end point </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: More pramlintide- than placebo-treated patients achieved the composite end point (25 vs. 7%; P &lt; 0.001) </plain></SENT>
<SENT sid="7" pm="."><plain>Reductions (means +/- SE) in A1C (-0.70 +/- 0.11% vs. -0.36 +/- 0.08%; P &lt; 0.05) and <z:chebi fb="73" ids="53262">PPG</z:chebi> increments (-24.4 +/- 3.6 mg/dl vs. -0.4 +/- 3.0 mg/dl; P &lt; 0.0001) were greater in pramlintide- versus placebo-treated patients, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>Glycemic improvements were accompanied by progressive <z:hpo ids='HP_0001824'>weight loss</z:hpo> with pramlintide and <z:mp ids='MP_0005456'>weight gain</z:mp> with placebo (-1.6 +/- 0.3 kg vs. +0.7 +/- 0.3 kg; P &lt; 0.0001) </plain></SENT>
<SENT sid="9" pm="."><plain>No treatment-related severe <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> occurred </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Pramlintide improved multiple glycemic parameters and <z:mp ids='MP_0001262'>reduced weight</z:mp> with no increase in <z:hpo ids='HP_0001943'>hypoglycemia</z:hpo> in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> who were not achieving glycemic targets with basal insulin with or without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">OAs</z:e> </plain></SENT>
</text></document>